Literature DB >> 7272892

Estrogen receptor protein in breast cancer as a predictor of recurrence.

D W Kinne, R Ashikari, A Butler, C Menendez-Botet, P P Rosen, M Schwartz.   

Abstract

Estrogen receptor protein (ERP) determinations of primary cancers of 1034 patients with primary breast cancer were done. ERP-positive patients tended to have a lower recurrence rate and had significantly improved survival. This difference was most apparent in patients with four or more axillary nodes involved. ERP-positive patients who recurred had a better survival. ERP did not influence response that adjuvant chemotherapy, nor did the presence of progesterone receptor or femtomole level of ERP affect recurrence.

Entities:  

Mesh：

Substances：

Year:  1981        PMID： 7272892     DOI： 10.1002/1097-0142(19810515)47:10<2364::aid-cncr2820471007>3.0.co;2-s

Source DB:  PubMed          Journal:  Cancer        ISSN： 0008-543X            Impact factor:   6.860


  26 in total

1.  Detection of axillary lymph node metastases in breast carcinoma by technetium-99m sestamibi breast scintigraphy, ultrasound and conventional mammography.

Authors:  W W Lam; W T Yang; Y L Chan; I E Stewart; C Metreweli; W King
Journal:  Eur J Nucl Med       Date:  1996-05

2.  Relationship of estrogen and progesterone receptors to prognosis in breast cancer.

Authors:  G A Gelbfish; A L Davidson; S Kopel; B Schreibman; J S Gelbfish; G A Degenshein; B L Herz; J N Cunningham
Journal:  Ann Surg       Date:  1988-01       Impact factor: 12.969

3.  A prospective analysis of immunohistochemically determined hormone receptors and nuclear features as predictors of early recurrence in primary breast cancer.

Authors:  M Stierer; H Rosen; R Weber; H Hanak; L Auerbach; J Spona; H Tüchler
Journal:  Breast Cancer Res Treat       Date:  1995       Impact factor: 4.872

4.  Studies on estradiol receptors in human mammary carcinomas.

Authors:  M J Duffy; M O'Connell; L McDonnell; C E Connolly; B Cantwell; J J Fennelly; R Conroy
Journal:  Ir J Med Sci       Date:  1984-11       Impact factor: 1.568

5.  Disease-free interval and estrogen receptor activity in tumor tissue of patients with primary breast cancer: analysis after long-term follow-up.

Authors:  J M Raemaekers; L V Beex; A J Koenders; G F Pieters; A G Smals; T J Benraad; P W Kloppenborg
Journal:  Breast Cancer Res Treat       Date:  1985       Impact factor: 4.872

6.  Immuno-biochemical assay for determination of nuclear steroid receptors during tamoxifen therapy.

Authors:  A Vering; A Vockel; M Stegmüller; H G Bender
Journal:  J Cancer Res Clin Oncol       Date:  1993       Impact factor: 4.553

Review 7.  Practical breast carcinoma cell kinetics: review and update.

Authors:  J S Meyer; R W McDivitt; K R Stone; M U Prey; W C Bauer
Journal:  Breast Cancer Res Treat       Date:  1984       Impact factor: 4.872

8.  Monoclonal antibody detection of a circulating tumor-associated antigen. I. Presence of antigen in sera of patients with colorectal, gastric, and pancreatic carcinoma.

Authors:  M Herlyn; H F Sears; Z Steplewski; H Koprowski
Journal:  J Clin Immunol       Date:  1982-04       Impact factor: 8.317

Review 9.  The predictive value of steroid hormone receptor analysis in breast, endometrial and ovarian cancer.

Authors:  R Vihko; A Alanko; V Isomaa; A Kauppila
Journal:  Med Oncol Tumor Pharmacother       Date:  1986

10.  Prognostic value of estrogen and progesterone receptors in primary breast cancer.

Authors:  S Saez; F Cheix; B Asselain
Journal:  Breast Cancer Res Treat       Date:  1983       Impact factor: 4.872
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.